Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRd followed by cilta-cel versus VRd followed by Rd in transplant-not-planned newly diagnosed multiple myeloma
NL-OMON56056Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON56056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56056.